First-Line Medication Treatment for Adolescents ≥13 Years with ADHD

Primary Medication Recommendations

The American Academy of Pediatrics recommends stimulant medications as first-line treatment for adolescents with ADHD, with methylphenidate or amphetamine-based stimulants demonstrating 70-80% response rates and the strongest evidence for efficacy 1, 2
Stimulant medications are the preferred first-line pharmacotherapy for adolescents with ADHD, with the American Academy of Pediatrics providing a strong recommendation (Grade A evidence) for FDA-approved stimulants in patients aged 12-18 years 1, 2
Long-acting formulations are strongly preferred over immediate-release preparations due to better medication adherence, more consistent symptom control throughout the day, reduced rebound effects, and lower diversion potential 2, 4

The American Academy of Pediatrics recommends considering non-stimulants only when stimulants are contraindicated, not tolerated, or have failed after adequate trials of both methylphenidate and amphetamine classes 2
Atomoxetine is preferred in patients with active substance abuse history as it is a non-controlled substance, with a target dose of 60-100 mg daily and requires 2-4 weeks for initial effect and 6-12 weeks for full therapeutic benefit 2, 4
Extended-release guanfacine and clonidine are FDA-approved as monotherapy or adjunctive therapy with stimulants, with an effect size around 0.7 and are particularly useful when comorbid sleep disturbances, tics, or oppositional symptoms are present 1, 2

The treatment algorithm recommends starting with a long-acting stimulant, and if inadequate response, trial the other stimulant class before moving to non-stimulants 1, 2
If both stimulant classes fail or are not tolerated, consider atomoxetine as the only FDA-approved non-stimulant for adolescent ADHD 2, 4

The American Academy of Pediatrics recommends monitoring blood pressure and pulse at baseline and regularly during treatment, as well as height and weight monitoring, particularly in younger adolescents 2, 4
Screen for substance abuse disorder before prescribing stimulants, and monitor for sleep disturbances and appetite changes 2, 4

In cases of active substance abuse disorder, consider long-acting stimulant formulations with lower abuse potential first, and atomoxetine as a non-controlled substance alternative 2, 4
In cases of comorbid anxiety or depression, stimulants remain first-line, and if ADHD symptoms improve but mood/anxiety symptoms persist, add an SSRI to the stimulant regimen 3, 4
In cases of cardiovascular concerns, avoid stimulants in uncontrolled hypertension, symptomatic cardiovascular disease, or structural heart defects, and consider atomoxetine or alpha-2 agonists as alternatives 2, 4